Taranabant, a novel cannabinoid type 1 receptor inverse agonist.
Merck & Co Inc is developing the cannabinoid receptor type 1 inverse agonist taranabant for the potential treatment of obesity and nicotine dependence. By October 2006, the drug had entered phase III trials for obesity, and by May 2008, a phase II study of taranabant as an aid to smoking cessation in chronic cigarette smokers had been completed.
Fremming
Bradley A
BA
University of Nebraska Medical Center, College of Medicine, Michael F Sorrell Center for Health Science Education, 15926 S St, Omaha, NE 68135, USA. bfremming@unmc.edu
Boyd
Steven T
ST
D000577:Amides / Q000009:adverse effects / Q000493:pharmacokinetics / Q000627:therapeutic use*; D000818:Animals; D019440:Anti-Obesity Agents / Q000009:adverse effects / Q000493:pharmacokinetics / Q000627:therapeutic use*; D017321:Clinical Trials, Phase I as Topic; D017322:Clinical Trials, Phase II as Topic; D017326:Clinical Trials, Phase III as Topic; D000075202:Contraindications; D004345:Drug Industry; D006801:Humans; D009765:Obesity / Q000188:drug therapy; D010330:Patents as Topic; D011725:Pyridines / Q000009:adverse effects / Q000493:pharmacokinetics / Q000627:therapeutic use*; D043884:Receptor, Cannabinoid, CB1 / Q000819:agonists*; D013329:Structure-Activity Relationship; D014029:Tobacco Use Disorder / Q000188:drug therapy*
D000577:Amides; D019440:Anti-Obesity Agents; D011725:Pyridines; D043884:Receptor, Cannabinoid, CB1; C521311:N-(3-(4-chlorophenyl)-2-(3-cyanophenyl)-1-methylpropyl)-2-methyl-2-((5-(trifluoromethyl)pyridin-2-yl)oxy)propanamide